Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029 [Yahoo! Finance]
Lifecore Biomedical (LFCR) was upgraded by Barrington Research from "market perform" to "outperform". They now have a $5.50 price target on the stock.
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift [Seeking Alpha]